900 Middlefield Road
4th Floor
Redwood City, CA 94063
United States
650 980 9099
https://biomeafusion.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 103
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Thomas Andrew Butler | Co-Founder, Chairman & CEO | 921.14k | N/A | 1981 |
Mr. Ramses M. Erdtmann | Co-Founder, President, COO & Director | 659.53k | N/A | 1963 |
Mr. Franco Valle | CFO & Principal Accounting Officer | 651.77k | N/A | 1981 |
Mr. Heow Tan | Chief Technology & Quality Officer | N/A | N/A | 1959 |
Ms. Naomi Cretcher | Chief People Officer | N/A | N/A | N/A |
Dr. Thorsten Kirschberg Ph.D. | Executive Vice President of Chemistry | N/A | N/A | 1970 |
Dr. Stephan Morris M.D. | Chief Development Officer | N/A | N/A | N/A |
Mr. Ravi Upasani | Executive Vice President of Intellectual Property | N/A | N/A | N/A |
Dr. Juan Pablo Frias M.D. | Chief Medical Officer | N/A | N/A | N/A |
Caroline Perez- Dupont | Senior Vice President of Contracts | N/A | N/A | N/A |
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Biomea Fusion, Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 6; Board: 9; Shareholder rights: 8; Compensation: 9.